Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 4/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | POLQ | O75417 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3647884 | 0.80 | IDO1 (0.59) | IDO1ALDH1A1KDM4EATMMAOB | |
| SCHEMBL17329111 | 0.80 | IDO1 (0.59) | IDO1ALDH1A1KDM4EATMMAOB | |
| SCHEMBL2097721 | 0.78 | IDO1 (0.57) | IDO1ALDH1A1KDM4EATMMAOB | |
| SCHEMBL29389277 | 0.78 | IDO1 (0.57) | IDO1ALDH1A1KDM4EATMMAOB | |
| SCHEMBL4527 | 0.78 | IDO1 (0.57) | IDO1ALDH1A1KDM4EATMMAOB | |
| SCHEMBL44837 | 0.78 | IDO1 (0.57) | IDO1ALDH1A1KDM4EATMMAOB | |
| SCHEMBL29427013 | 0.78 | IDO1 (0.57) | IDO1ALDH1A1KDM4EATMMAOB | |
| SCHEMBL23337251 | 0.76 | IDO1 (0.55) | IDO1ALDH1A1KDM4EATMMAOB | |
| SCHEMBL14162147 | 0.76 | IDO1 (0.55) | IDO1ALDH1A1KDM4EATMMAOB | |
| SCHEMBL20083527 | 0.76 | IDO1 (0.55) | IDO1ALDH1A1KDM4EATMMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763562-B2 | Heteroatom bridged metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20070135597-A1 | Heteroatom bridged metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135597-A1 | Heteroatom bridged metallocene compounds for olefin polymerization | AP2M1, AP1M1, PYM1 | IDO1 1090/4885ALDH1A1 4332/4885KDM4E 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.